StemCell Therapy

The following discussion and analysis should be read together with our unauditedcondensed consolidated financial statements and related notes thereto set forthin this Quarterly Report on Form 10-Q as well as our Annual Report on Form 10-Kfor the year ended December 31, 2019.This Form 10-Q contains "forward-looking statements" that indicate certain risksand uncertainties, many of which are beyond our control. Actual results coulddiffer materially and adversely from those anticipated in such forward-lookingstatements as a result of certain factors, including those set forth below andelsewhere in this report. Important factors that may cause actual results todiffer from projections include: We may not be able to continue operating without additional financing; Current negative operating cash flows; The terms of any further financing, which may be highly dilutive and may include onerous terms; Significant debt repayments due between June and September 2020, which the Company will likely need to extend or

restructure, with

associated with

pandemic, which

Our precision medicine business, conducted in our Helomics division, iscommitted to improving the effectiveness of cancer therapy using ourproprietary, multi-omic tumor profiling platform, one-of-a-kind database ofhistorical tumor data, and the power of AI to build predictive models of tumordrug response.

Contract Research Organization (CRO) and AI-Driven Business

Patient enrichment & selection for trials

Clinical trial optimization

Via our Helomics subsidiary, we offer a group of clinically relevant,cancer-related tumor profiling and biomarker tests for gynecological cancersthat determine how likely the patient is to respond to various types ofchemotherapy and which therapies might be indicated by relevant tumorbiomarkers.

Skyline Medical - The STREAMWAY System

STREAMWAY System Product Sales

We sell our medical device products directly to hospitals and other medicalfacilities using employed sales representatives, independent contractors anddistributors.

Comparison of three-month periods ended March 31, 2020 and March 31, 2019

Operations expense. Operations expense primarily consists of expenses related toproduct development and prototyping and testing in our current stage.

Liquidity and Capital Resources

Net cash used in operating activities was $2,972,981 and $2,048,653 for thethree months ended March 31, 2020 and March 31, 2019, respectively. Cash used inoperating activities increased in the 2020 period primarily because of theincrease in total operating expense and the additional costs related to theHelomics business.

Liquidity, Plan of Financing, and Going Concern Qualification

We have funded our operations through a combination of debt and equityinstruments including short term borrowings, and a variety of debt and equityofferings.

February 2020 Convertible Note

March 2020 Private Placement of Common Stock and Warrants

March 2020 Amendments to and Extensions of Promissory Notes

April 2020 Paycheck Protection Program

May 2020 Registered Direct Offering of Common Stock and Concurrent PrivatePlacement of Warrants

Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet activities as defined in Item303(a)(4) of Regulation S-K.

Accounting Standards and Recent Accounting Developments

See Note 1 - Summary of Significant Accounting Policies to the unaudited,Condensed Consolidated Financial Statements of this Quarterly Report on Form10-Q for a discussion of recent accounting developments.

Edgar Online, source Glimpses

Link:
PREDICTIVE ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com

This entry was posted on June 9, 2020 at 9:43 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |